64Cu-LLP2A for Imaging Multiple Myeloma

Inclusion Criteria:

• Adult patients 18 years of age or older with clinically or pathologically defined MMin accordance with International Myeloma Working Group or as stated in office note /clinical assessment from treating physician.

*All types of active myeloma are eligible including both newly diagnosed andpreviously treated provided plans are to start a new treatment or restart a priortreatment.

• Healthy Volunteer Subjects: Adult 18 years of age or older with no known hematologicdisorder such as anemia, leukemia, etc. who is considered healthy based onassessment by PI. (Cohort 1 only).

• Able to give informed consent.

• Does not have any exclusions related to PET/MR imaging: No implanted medical devicessuch as: pacemaker, defibrillator, neurostimulator, artificial heart valve, cerebralaneurysm clips, no accidental exposure to metal fragments (if applicable)

• If applicable for administration of contrast with MRI imaging subject must have acalculated GFR of at least 60 mg/mL/1.73 m^2.

• Not currently pregnant or nursing: Subject must be surgically sterile (has had adocumented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearingpotential for whom a urine pregnancy test (with the test performed within the 24hour period immediately prior to administration of 64Cu-LLP2A) is negative.

Exclusion Criteria:

• Patients with other invasive malignancies, with the exception of non-melanoma skincancer, who had (or have) any evidence of the other cancer present within the last 5years.

• Unable to tolerate up to 90 min of PET/MR or PET/CT imaging per imaging session.